Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALEC Alector	$2.27 +3.2%	$1.68	$0.87 ▼ $6.37	$222.67M	0.86	1.57 million shs	676,535 shs
CRON Cronos Group	$2.56 +5.8%	$2.11	$1.60 ▼ $2.77	$926.95M	1.01	3.01 million shs	2.80 million shs
IMNM Immunome	$9.95 +4.0%	$9.67	$5.15 ▼ $16.73	$833.02M	1.93	630,503 shs	366,385 shs
QURE uniQure	$15.55 +0.5%	$14.55	$4.45 ▼ $19.18	$849.34M	0.11	1.14 million shs	823,711 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALEC Alector	+1.85%	+0.96%	+35.80%	+67.94%	-57.77%
CRON Cronos Group	-2.42%	-7.63%	+15.79%	+18.05%	+2.54%
IMNM Immunome	-4.49%	-4.40%	-11.55%	+13.12%	-37.08%
QURE uniQure	+0.98%	+6.03%	+6.76%	+1.64%	+128.32%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALEC Alector	3.6161 of 5 stars	3.1	2.0	4.5	1.1	2.5	0.0
CRON Cronos Group	0.9408 of 5 stars	0.0	3.0	0.0	2.7	0.0	1.3
IMNM Immunome	1.8463 of 5 stars	3.5	0.0	0.0	2.6	2.5	0.0
QURE uniQure	2.8388 of 5 stars	3.5	1.0	0.0	3.9	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALEC Alector	2.29	Hold	$4.17	83.55% Upside
CRON Cronos Group	0.00	N/A	N/A	N/A
IMNM Immunome	3.00	Buy	$23.14	132.59% Upside
QURE uniQure	3.00	Buy	$37.45	140.87% Upside

Current Analyst Ratings Breakdown

Latest ALEC, CRON, IMNM, and QURE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2025	QURE uniQure	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Outperform	$30.00
8/7/2025	IMNM Immunome	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$23.00 ➝ $22.00
8/7/2025	IMNM Immunome	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$21.00
7/30/2025	QURE uniQure	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$47.00
7/29/2025	QURE uniQure	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$38.00 ➝ $35.00
7/28/2025	ALEC Alector	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Outperform	$2.50 ➝ $3.50
5/30/2025	QURE uniQure	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$38.00
5/29/2025	QURE uniQure	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$70.00

(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALEC Alector	$100.56M	2.28	N/A	N/A	$0.70 per share	3.24
CRON Cronos Group	$117.61M	8.34	$0.00 per share	5,329.67	$2.95 per share	0.87
IMNM Immunome	$9.04M	95.80	N/A	N/A	$3.09 per share	3.22
QURE uniQure	$27.12M	31.46	N/A	N/A	($0.07) per share	-222.14

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALEC Alector	-$119.05M	-$1.16	N/A	N/A	N/A	-142.10%	-112.06%	-26.37%	11/5/2025 (Estimated)
CRON Cronos Group	$41.08M	$0.05	51.20	85.33	N/A	14.19%	-3.78%	-3.62%	N/A
IMNM Immunome	-$292.96M	-$3.08	N/A	N/A	N/A	-1,687.08%	-76.10%	-65.14%	N/A
QURE uniQure	-$239.56M	-$3.92	N/A	N/A	N/A	-1,387.98%	-1,010.74%	-33.27%	11/4/2025 (Estimated)

Latest ALEC, CRON, IMNM, and QURE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	ALEC Alector	-$0.45	-$0.30	+$0.15	-$0.30	$2.76 million	$7.87 million
8/7/2025	Q2 2025	CRON Cronos Group	-$0.02	-$0.10	-$0.08	-$0.10	$45.73 million	$33.46 million
8/6/2025	Q2 2025	IMNM Immunome	-$0.52	-$0.50	+$0.02	-$0.50	$1.03 million	$4.02 million
7/29/2025	Q2 2025	QURE uniQure	-$0.89	-$0.69	+$0.20	-$0.69	$5.00 million	$5.26 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALEC Alector	N/A	N/A	N/A	N/A	N/A
CRON Cronos Group	N/A	N/A	N/A	N/A	N/A
IMNM Immunome	N/A	N/A	N/A	N/A	N/A
QURE uniQure	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALEC Alector	0.13	3.78	3.78
CRON Cronos Group	N/A	24.65	23.53
IMNM Immunome	N/A	12.13	12.13
QURE uniQure	1.53	9.98	9.98

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALEC Alector	85.83%
CRON Cronos Group	8.71%
IMNM Immunome	44.58%
QURE uniQure	78.83%

Insider Ownership

Company	Insider Ownership
ALEC Alector	9.70%
CRON Cronos Group	7.30%
IMNM Immunome	7.69%
QURE uniQure	4.79%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALEC Alector	270	101.21 million	91.39 million	Optionable
CRON Cronos Group	450	383.04 million	355.08 million	Optionable
IMNM Immunome	40	87.04 million	80.35 million	Optionable
QURE uniQure	500	54.87 million	52.24 million	Optionable

ALEC, CRON, IMNM, and QURE Headlines

Recent News About These Companies

Wall Street Analysts Think uniQure (QURE) Could Surge 142.67%: Read This Before Placing a Bet

July 31, 2025 | zacks.com

uniQure N.V. (QURE) Q2 2025 Earnings Call Transcript

July 29, 2025 | seekingalpha.com

uniQure Narrows Loss in Fiscal Q2

July 29, 2025 | fool.com

uniQure (QURE) Reports Q2 Loss, Misses Revenue Estimates

July 29, 2025 | zacks.com

uniQure Announces Second Quarter 2025 Financial Results and Highlights of Recent Company Progress

July 29, 2025 | globenewswire.com

uniQure to Announce Second Quarter 2025 Financial Results

July 22, 2025 | globenewswire.com

uniQure: Price And Value Have Caught Up

June 17, 2025 | seekingalpha.com

uniQure Announces Appointment of Kylie O'Keefe as Chief Customer and Strategy Officer

June 11, 2025 | globenewswire.com

uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease

June 2, 2025 | globenewswire.com

3 Top Genomics Stocks to Add to Your Portfolio in 2025

May 21, 2025 | zacks.com

Wall Street Analysts See a 161.51% Upside in uniQure (QURE): Can the Stock Really Move This High?

May 14, 2025 | zacks.com

uniQure N.V. (QURE) Q1 2025 Earnings Call Transcript

May 9, 2025 | seekingalpha.com

UniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates

May 9, 2025 | zacks.com

uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress

May 9, 2025 | globenewswire.com

uniQure to Announce First Quarter 2025 Financial Results

May 5, 2025 | globenewswire.com

uniQure (QURE) Moves 38.5% Higher: Will This Strength Last?

April 21, 2025 | zacks.com

uniQure: Huntington's Gene Therapy Advances, But Commercial Hurdles Keep This A Hold

April 21, 2025 | seekingalpha.com

uniQure: Bullish On Near-Term Catalysts After Breakthrough Therapy Designation For AMT-130

April 21, 2025 | seekingalpha.com

uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington's Disease

April 17, 2025 | globenewswire.com

UniQure (QURE) Reports Q4 Loss, Misses Revenue Estimates

February 27, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ALEC, CRON, IMNM, and QURE Company Descriptions

Alector NASDAQ:ALEC

$2.27 +0.07 (+3.18%)

Closing price 04:00 PM Eastern

Extended Trading

$2.28 +0.00 (+0.22%)

As of 07:47 PM Eastern

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

Cronos Group NASDAQ:CRON

$2.56 +0.14 (+5.79%)

Closing price 04:00 PM Eastern

Extended Trading

$2.56 0.00 (-0.20%)

As of 07:58 PM Eastern

Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.

Immunome NASDAQ:IMNM

$9.95 +0.38 (+3.97%)

Closing price 04:00 PM Eastern

Extended Trading

$9.95 0.00 (0.00%)

As of 06:40 PM Eastern

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

uniQure NASDAQ:QURE

$15.55 +0.07 (+0.45%)

Closing price 04:00 PM Eastern

Extended Trading

$15.48 -0.08 (-0.48%)

As of 06:17 PM Eastern

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time